prinomastat and Carcinoma--Pancreatic-Ductal

The present study was aimed at evaluating the effect of the matrix metalloproteinase (MMP) inhibitor prinomastat (AG3340) on tumor progression using an orthotopic pancreatic carcinoma model in severe combined immunodeficient mice. In controls, receiving vehicle only, the poorly differentiated ductal adenocarcinoma invaded into adjacent organs and metastasized to different sites in the abdomen and to the lungs. Treatment with prinomastat, intraperitoneally twice daily for 21 days, reduced primary tumor volume significantly to 19.0 (+/-7.7)% of control, with induction of necrosis, differentiation, and fibrotic tissue in the pancreatic tumors. Invasion was not observed in 63% of prinomastat-treated mice, and metastases were reduced markedly. Surprisingly, prinomastat-treated tumors had on average higher microvessel densities as a consequence of an increased angiogenesis in perinecrotic tumor areas. We conclude that prinomastat is highly effective in inhibiting pancreatic carcinoma growth and progression in an orthotopic cancer model. This model appears to be a valuable tool to investigate the potency of novel antimetastatic strategies in pancreatic ductal adenocarcinoma by specifically targeting certain MMPs.

Topics: Adenocarcinoma; Animals; Antigens, CD34; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Differentiation; Female; Fibrosis; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase Inhibitors; Mice; Mice, SCID; Necrosis; Neoplasm Invasiveness; Neoplasm Transplantation; Organic Chemicals; Pancreatic Neoplasms; Tumor Cells, Cultured